RESPICARDIA
Respicardia (formerly Cardiac Concepts) is dedicated to improving the lives of heart failure patients by developing implantable therapies designed to improve respiratory rhythm management and cardiovascular health. The first product, the remedē® System, is an implantable stimulation device that is designed to restore a more normal breathing pattern during sleep for patients with central sleep apnea. Respicardia® is committed to improving cardiovascular health…one breath at a time™.
RESPICARDIA
Social Links:
Industry:
Health Care Medical Device Therapeutics
Founded:
2006-01-01
Address:
Minnetonka, Minnesota, United States
Country:
United States
Website Url:
http://www.respicardia.com
Total Employee:
11+
Status:
Active
Contact:
(952)540-4470
Email Addresses:
[email protected]
Total Funding:
160.19 M USD
Technology used in webpage:
SPF Domain Not Resolving Microsoft Exchange Online Amazon Office 365 Mail IPv6 Microsoft Azure DNS Microsoft Gravity Forms Fastly Hosted
Similar Organizations
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Current Advisors List
Current Employees Featured
Founder
Investors List
ZOLL Medical Corporation
ZOLL Medical Corporation investment in Venture Round - Respicardia
Polaris Venture Capital
Polaris Venture Capital investment in Venture Round - Respicardia
Sorin Group
Sorin Group investment in Venture Round - Respicardia
Versant Ventures
Versant Ventures investment in Venture Round - Respicardia
Sorin Group
Sorin Group investment in Debt Financing - Respicardia
Sorin Group
Sorin Group investment in Venture Round - Respicardia
Affinity Capital Management
Affinity Capital Management investment in Series D - Respicardia
Ares Capital Corporation
Ares Capital Corporation investment in Debt Financing - Respicardia
Three Arch Partners
Three Arch Partners investment in Series C - Respicardia
Affinity Capital Management
Affinity Capital Management investment in Series C - Respicardia
Official Site Inspections
http://www.respicardia.com
- Host name: 151.101.2.159
- IP address: 151.101.2.159
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Respicardia"
About - remedē® System
Founded in 2006 and acquired by ZOLL in 2021, Respicardia is a leader in technologies that address the unmet needs of people with Central Sleep Apnea (CSA). CSA results from the …See details»
ZOLL Medical Corporation acquires Respicardia, Inc.
Apr 12, 2021 · — ZOLL ® Medical Corporation, an Asahi Kasei company that manufactures medical devices and related software solutions, today announced that it has acquired …See details»
Central Sleep Apnea (CSA) Treatment | remedē® System
Central sleep apnea is a serious disorder that causes disrupted breathing during sleep. Know the symptoms, causes, and how to find out if you have CSA. Learn about an FDA approved non …See details»
Central Sleep Apnea (CSA) Treatment | Respicardia
Founded in 2006 and headquartered in Minnesota, Respicardia is a leader in innovative technologies that address the unmet needs of people with Central Sleep Apnea (CSA). CSA …See details»
Respicardia - Crunchbase Company Profile & Funding
Respicardia (formerly Cardiac Concepts) is dedicated to improving the lives of heart failure patients by developing implantable therapies designed to improve respiratory rhythm …See details»
remedē® | Innovative treatment for Central Sleep Apnea
The rem edÄ“ System is an implantable system that stimulates a nerve in the chest (phrenic nerve) to send signals to the large muscle that controls breathing (the diaphragm). These signals stimulate breathing in the same way that the brain …See details»
remedē® | Innovative treatment for Central Sleep Apnea
In 2018, CMS granted the remedÄ“ System the new technology add-on payment and the transitional pass-through (TPT) payment. These programs recognize innovative medical technologies that substantially improve the diagnosis or …See details»
FDA approves Remedē implantable device to treat …
Oct 6, 2017 · The FDA granted approval of RemedÄ“ System to Respicardia Inc. The RemedÄ“ System comprises a battery pack surgically placed under the skin in the upper chest area and small, thin wires that are inserted into the blood …See details»
ZOLL Medical Corporation, an Asahi Kasei company, …
Apr 12, 2021 · ZOLL Medical Corporation (ZOLL), an Asahi Kasei company, has acquired Respicardia, Inc. (Respicardia), a U.S. medical equipment company which manufactures and sells the remedē® System, an implantable …See details»
Remedē System Efficacious and Well-Tolerated in …
May 25, 2021 · Results from a 5-year, post-approval study (PAS) of the remedÄ“ System (NCT03425188), a transvenous phrenic nerve stimulation (TPNS) therapy device by ZOLL Respicardia, suggest that long-term TPNS safely improves …See details»
Central Sleep Apnea (CSA) - remedē® System
Excessive daytime sleepiness, a lack of energy during the day, or pauses in breathing at night may all be symptoms of a serious sleep disorder called central sleep apnea (CSA). What is central sleep apnea? Most people associate …See details»
FDA approves implantable device to treat moderate to severe …
The RemedÄ“ System is an implantable device that stimulates a nerve located in the chest that is responsible for sending signals to the diaphragm to stimulate breathing.See details»
FDA approves new phrenic nerve stimulator for central sleep …
Nov 9, 2017 · The remedÄ“ System (Respicardia) consists of a pacemaker-like battery pack that’s surgically implanted in the upper chest beneath the skin. Wires electrically stimulate the …See details»
Transvenous Phrenic Nerve Stimulation for Central Sleep Apnea
RespiCardia remedÄ“ System (Minnetonka, MN 2017), a transvenous phrenic nerve stimulator, is indicated to treat central sleep apnea (CSA) by stimulating the phrenic nerve to cause …See details»
Getting remedē® for Central Sleep Apnea (CSA) - remedē® System
Interested in rem edÄ“? If you think the rem edÄ“ System may be the right treatment for your central sleep apnea (CSA), follow these steps to receive and properly adjust to your system. rem edÄ“ …See details»
5-Year Study Confirms Safety, Efficacy, Beneficial Effects of …
May 19, 2021 · The remedÄ“ System, the only implantable device approved by the US Food and Drug Administration (FDA) to treat moderate to severe CSA in adult patients with reduced …See details»
FDA Approves Implanted Device to Treat Central Sleep Apnea
Oct 8, 2017 · System to Respicardia Inc. The RemedÄ“ System is an implantable device that stimulates a nerve located in the chest responsible for sending signals to the diaphragm to …See details»
Treatment Benefits of the rem - remedē® System
Jul 10, 2019 · Respicardia, Inc., the manufacturer of the only FDA-approved active implantable device for the treatment of central sleep apnea (CSA), today announced the publication of the …See details»
Treatment Benefits of the remedē® System Sustained Through 36 …
Jul 10, 2019 · Founded in 2006 and headquartered near Minneapolis, Minn., Respicardia is dedicated to improving patient outcomes, quality of life and overall cardiovascular health via …See details»
Respicardia’s remedē® System Receives FDA Approval
Oct 10, 2017 · Respicardia, Inc., a private medical technology company, announced today that it received U.S. Food and Drug Administration (FDA) approval of its rem edÄ“ ® System, a …See details»